GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Simcere Pharmaceutical Group Ltd (HKSE:02096) » Definitions » Cash, Cash Equivalents, Marketable Securities

Simcere Pharmaceutical Group (HKSE:02096) Cash, Cash Equivalents, Marketable Securities : HK$2,208 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Simcere Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities?

Simcere Pharmaceutical Group's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 (HK$2,928.63 Mil) to Jun. 2023 (HK$2,687.68 Mil) but then stayed the same from Jun. 2023 (HK$2,687.68 Mil) to Dec. 2023 (HK$2,207.57 Mil).

Simcere Pharmaceutical Group's annual cash, cash equivalents, marketable securities increased from Dec. 2021 (HK$2,673.28 Mil) to Dec. 2022 (HK$2,928.63 Mil) but then declined from Dec. 2022 (HK$2,928.63 Mil) to Dec. 2023 (HK$2,207.57 Mil).


Simcere Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Simcere Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Simcere Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Chart

Simcere Pharmaceutical Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial 1,003.48 3,880.96 2,673.28 2,928.63 2,207.57

Simcere Pharmaceutical Group Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,673.28 3,347.10 2,928.63 2,687.68 2,207.57

Simcere Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Simcere Pharmaceutical Group  (HKSE:02096) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Simcere Pharmaceutical Group Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Simcere Pharmaceutical Group's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Simcere Pharmaceutical Group (HKSE:02096) Business Description

Industry
Traded in Other Exchanges
Address
No. 699-18, Xuanwu Road, Xuanwu District, Jiangsu, Nanjing, CHN, 210042
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Executives
Wang Xi 2305 Beneficiary of a trust
Ren Jinsheng 2202 Interest of your spouse
Right Wealth Holdings Limited 2501 Other
Wang Xi 2501 Other
Simcere Investments Group Limited 2501 Other
Excel Investments Group Limited 2501 Other
Simcere Pharmaceutical Holding Limited 2501 Other
Simcere Holding Limited 2501 Other
Artking Global Limited 2501 Other
Ren Zhen 2501 Other
Ren Yong 2501 Other
Ren Weidong 2501 Other
Peng Suqin 2501 Other
P&h Holdings Group Ltd. 2501 Other
Li Shimeng 2501 Other

Simcere Pharmaceutical Group (HKSE:02096) Headlines

No Headlines